|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0015249,
umls-concept:C0017262,
umls-concept:C0030705,
umls-concept:C0033684,
umls-concept:C0040085,
umls-concept:C0087111,
umls-concept:C0185117,
umls-concept:C0332293,
umls-concept:C1519810,
umls-concept:C1527249,
umls-concept:C2911684
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2011-1-12
|
|
pubmed:abstractText |
Thymidylate synthase (TS) and excision repair complementing-1 (ERCC-1) were known to be important biomarkers to predict a tumor response to 5-fluorouracil (5-FU) and oxaliplatin, but the relationship between these expressions and tumor response were still unclear. The aim of this study was to determine whether the expression of TS and ERCC-1 protein predict a tumor response in patients with unresectable colorectal cancer treated with mFOLFOX6 therapy as first-line treatment. Fifty patients with unresectable colorectal cancer treated with mFOLFOX6 therapy were enrolled in this study. The expression of TS and ERCC-1 protein in primary cancer cells were examined using immunohistochemistry. There were no significant differences between response rate and the expression of TS or ERCC-1 protein (TS: p>0.99, ERCC-1: p= 0.50). There were no significant differences between progression-free survival time and the expression of TS or ERCC-1 protein (TS: p=0.60, ERCC-1: p=0.60). In this study, the expression TS and ERCC-1 protein may not be useful for the prediction of tumor response in patients with unresectable colorectal cancer treated with mFOLFOX6 therapy.
|
|
pubmed:language |
jpn
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0385-0684
|
|
pubmed:author |
pubmed-author:HagaNorihiroN,
pubmed-author:IshibashiKeiichiroK,
pubmed-author:IshidaHideyukiH,
pubmed-author:IshiguroToruT,
pubmed-author:ItoyamaShinjiS,
pubmed-author:KumamotoKensukeK,
pubmed-author:KuwabaraKoukiK,
pubmed-author:MiuraIchiroI,
pubmed-author:MoriTakashiT,
pubmed-author:OhsawaTomonoriT,
pubmed-author:OkadaNorimichiN,
pubmed-author:TamaruJunichiJ,
pubmed-author:YamadaHirofumiH,
pubmed-author:YokoyamaMasaruM
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
37
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2532-5
|
|
pubmed:meshHeading |
pubmed-meshheading:21224630-Adult,
pubmed-meshheading:21224630-Aged,
pubmed-meshheading:21224630-Aged, 80 and over,
pubmed-meshheading:21224630-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21224630-Biological Markers,
pubmed-meshheading:21224630-Colorectal Neoplasms,
pubmed-meshheading:21224630-DNA-Binding Proteins,
pubmed-meshheading:21224630-Endonucleases,
pubmed-meshheading:21224630-Female,
pubmed-meshheading:21224630-Fluorouracil,
pubmed-meshheading:21224630-Humans,
pubmed-meshheading:21224630-Immunohistochemistry,
pubmed-meshheading:21224630-Leucovorin,
pubmed-meshheading:21224630-Male,
pubmed-meshheading:21224630-Middle Aged,
pubmed-meshheading:21224630-Organoplatinum Compounds,
pubmed-meshheading:21224630-Thymidylate Synthase,
pubmed-meshheading:21224630-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
[The expression of thymidylate synthase (TS) and excision repair complementing-1 (ERCC-1) protein in patients with unresectable colorectal cancer treated with mFOLFOX6 therapy].
|
|
pubmed:affiliation |
Dept. of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University.
|
|
pubmed:publicationType |
Journal Article,
English Abstract
|
